With no cure in sight, drugs firm LianBio begins exit strategy
The biotech, which obtained rights to novel drugs for use in the Chinese market, has announced a plan to wind up its business and delist from the Nasdaq just four…
Everest reaches new heights on growing drug sales
The innovative drug maker said its revenue soared more than 850% last year to between 124 million yuan and 126 million yuan Key Takeaways: Everest Medicines’ revenue soared nine-fold last…
FAST NEWS: Everest Medicines gets new drug license from Kezar Life
The latest: Everest Medicines Ltd. (1952.HK) announced Thursday that it has received an exclusive license from Kezar Life Sciences (KZR.US) to develop, manufacture and commercialize Zetomipzomib, a treatment for autoimmune diseases,…
After Ditching Promising Drug, Everest Medicines Bets on mRNA
The drug maker surprised investors last year when it halted its tie-up with Gilead to develop the breast cancer drug Trodelvy. Now it says it will focus on mRNA vaccinesKey…
FAST NEWS: Everest Medicines Hits New Low after New CEO Announcement
The latest: Innovative drug maker Everest Medicines Ltd. (1952.HK) on Monday announced the appointment of Luo Yongqing, formerly president and general manager of Greater China for Brii Biosciences Ltd. (2137.HK),…
Everest Medicines Descends to New Depths on String of Bad News
The drug maker’s shares hit all-time lows after it announced the loss of a key product, poor financial results and the resignation of its CEO Key Takeaways: The CEO of…
FAST NEWS: Everest Medicines Plunges After Terminating Breast Cancer Drug Deal
The latest: Everest Medicines Ltd. (1952.HK) announced Tuesday that it is terminating its agreement to develop Gilead Science’s (GILD.US) Sacituzumab Govitecan breast cancer drug for the China market. Looking up:…
Recent Articles
RELATED ARTICLES
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US -
Kintor shares plunge after hair-loss drug flops in clinical trials
9939.HK
-
Akeso marks profit milestone with swift rights issue
9926.HK
- InSilico seeks IPO boost to get AI drugs over the line
-
Adlai Nortye dives in Nasdaq debut, as key product faces hurdles
ANL.US
-
Drug maker Junshi seeks Swiss cure for cash woes
1877.HK 688150.SHG
